Yi Chen

发表

Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors.

A. Polonskaia, C. Lukacs, Hongmao Sun, 2013, Bioorganic & medicinal chemistry letters.

3,5,6-Trisubstituted naphthostyrils as CDK2 inhibitors.

U. Kammlott, C. Lukacs, Yi Chen, 2003, Bioorganic & medicinal chemistry letters.

A new series of potent oxindole inhibitors of CDK2.

Thelma Thompson, U. Kammlott, Yi Chen, 2004, Bioorganic & medicinal chemistry letters.

Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis.

Yi Chen, K. Luk, A. Railkar, 2006, Bioorganic & medicinal chemistry letters.

Discovery and in Vivo Evaluation of Dual PI3K-beta/delta inhibitors

D. Whittington, Yi Chen, K. Miner, 2012 .

Discovery and in vivo evaluation of dual PI3Kβ/δ inhibitors.

D. Whittington, Yi Chen, K. Miner, 2012, Journal of medicinal chemistry.

Potent and Orally Bioavailable GPR142 Agonists as Novel Insulin Secretagogues for the Treatment of Type 2 Diabetes.

Yi Chen, J. Reagan, M. Lizarzaburu, 2013, ACS medicinal chemistry letters.

Discovery and in vivo evaluation of (S)-N-(1-(7-fluoro-2-(pyridin-2-yl)quinolin-3-yl)ethyl)-9H-purin-6-amine (AMG319) and related PI3Kδ inhibitors for inflammation and autoimmune disease.

Xiaolin Hao, Ben Fisher, Andreas Reichelt, 2015, Journal of medicinal chemistry.

Identification of novel, potent and selective inhibitors of Polo-like kinase 1.

Yi Chen, Zhi Chen, K. Luk, 2012, Bioorganic & Medicinal Chemistry Letters.

Identification and optimization of N3,N6-diaryl-1H-pyrazolo[3,4-d]pyrimidine-3,6-diamines as a novel class of ACK1 inhibitors.

Xiaolin Hao, Holger Wesche, Shou-Hua Xiao, 2008, Bioorganic & medicinal chemistry letters.